G1 THERAPEUTICS (GTHX) Given Buy Rating at Cowen and Company

Cowen and Company reaffirmed their buy rating on shares of G1 THERAPEUTICS (NASDAQ:GTHX) in a report released on Wednesday.

“G1 Therapeutics ended Q2 with $133MM in cash following completion of an IPO in.”,” Cowen and Company’s analyst commented.

A number of other analysts also recently commented on the stock. Wedbush assumed coverage on shares of G1 THERAPEUTICS in a report on Monday, June 12th. They issued an outperform rating and a $31.00 price objective for the company. Needham & Company LLC assumed coverage on shares of G1 THERAPEUTICS in a report on Monday, June 12th. They issued a buy rating and a $34.00 price objective for the company. Finally, J P Morgan Chase & Co assumed coverage on shares of G1 THERAPEUTICS in a report on Monday, June 12th. They issued an overweight rating and a $23.00 price objective for the company.

Shares of G1 THERAPEUTICS (GTHX) traded up 1.43% during midday trading on Wednesday, reaching $12.77. The company’s stock had a trading volume of 17,364 shares. G1 THERAPEUTICS has a 52 week low of $12.04 and a 52 week high of $20.60. The stock’s market capitalization is $18.90 million. The company has a 50 day moving average price of $15.28 and a 200-day moving average price of $16.19.

G1 THERAPEUTICS (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($1.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.48. On average, equities research analysts expect that G1 THERAPEUTICS will post ($2.53) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2017/08/12/g1-therapeutics-gthx-given-buy-rating-at-cowen-and-company.html.

In other news, insider Ra Capital Healthcare Fund Lp purchased 400,000 shares of the business’s stock in a transaction dated Monday, May 22nd. The stock was acquired at an average price of $15.00 per share, for a total transaction of $6,000,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Clay Thorp purchased 133,333 shares of the business’s stock in a transaction dated Monday, May 22nd. The shares were purchased at an average price of $15.00 per share, with a total value of $1,999,995.00. The disclosure for this purchase can be found here. Insiders have bought a total of 833,333 shares of company stock valued at $12,499,995 in the last 90 days.

Hedge funds have recently made changes to their positions in the company. Alps Advisors Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter worth about $444,000. Victory Capital Management Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter worth about $889,000. Vanguard Group Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter worth about $1,291,000. Chartwell Investment Partners LLC purchased a new stake in shares of G1 THERAPEUTICS during the second quarter worth about $1,538,000. Finally, Laurion Capital Management LP purchased a new stake in shares of G1 THERAPEUTICS during the second quarter worth about $3,488,000. Institutional investors and hedge funds own 4.57% of the company’s stock.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply